Is It Time for Integrase Inhibitors to be the Preferred Regimen for the First-Line Treatment of HIV-1-Infected Naive Patients?
Jean Cyr Yombi 1, Anton Pozniak 2
1 Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; 2 NULL
*Correspondence: Anton Pozniak, Email not available
Abstract
Thanks to the emergence of combination antiretroviral therapy, HIV/AIDS has been transformed into a manageable, chronic condition in just 30 years and the life expectancy of patients living with HIV is now comparable to those without. Recent data (START) support the strategy of starting all HIV-positive patients regardless of CD4 count. However, patients and physicians want more than just viral control: they want better tolerability, convenience, and few drug-drug interactions. Are the guidelines right in recommending an integrase inhibitor-based regimen as the first-line treatment of choice?
